Comparison of dissolution properties of 2 enteric-coated formulations containing mycophenolate sodium: Myfortic vs Femulan.

@article{Esquivel2010ComparisonOD,
  title={Comparison of dissolution properties of 2 enteric-coated formulations containing mycophenolate sodium: Myfortic vs Femulan.},
  author={Abdieel Esquivel and Rodrigo Gonz{\'a}lez-Ram{\'i}rez and Josefina Alber{\'u} and Carmen Gracida and Mara Medeiros and Gilberto Casta{\~n}eda-Hern{\'a}ndez},
  journal={Transplantation proceedings},
  year={2010},
  volume={42 1},
  pages={353-6}
}
Enteric-coated tablets containing mycophenolate sodium have been developed to reduce gastric toxicity. The objective of this study was to compare 2 enteric-coated formulations containing 360 mg of mycophenolate sodium: the innovator product, Myfortic, and an agent that recently became available in Mexico, Femulan. For both formulations, mycophenolate sodium content was within the 90% to 110% range of the label claimed dose, and no impurities were present as determined at high-performance liquid… CONTINUE READING
4 Extracted Citations
9 Extracted References
Similar Papers

Referenced Papers

Publications referenced by this paper.
Showing 1-9 of 9 references

Comparison of issolution profile and plasma concentration – time profile of the halidomide formulations made by Japanese , Mexican and British ompanies

  • V Hernández-Abad, G Castañeda-Hernández, S García-iménez
  • Yakugaku Zasshi
  • 2008

Physiochemical proper - ies of generic formulations of tacrolimus in Mexico

  • E Palylyk-Colwell, F Jamali, W Dryden
  • Transplant roc
  • 2008

Report of the American ociety of Transplantation conference on immunosuppressive rugs and the use of generic immunosuppressants

  • BD Kahan
  • 2003

Bioequivalence nd interchangeability of narrow therapeutic range drugs : Cana - ian Society for Pharmaceutical Sciences discussion

  • L Buist
  • J Pharm ham Sci
  • 1998

Differences in he dissolution profile , suggesting a lower oral bioavailability , of a ovel formulation of oxcarbazepine ( Actinium ) compared to the nnovator product ( Trileptal )

  • Y Fujita, K Yamamoto, T Aomori
  • Proc West Pharmacol Soc

Guía técnica ara la presentación y evaluación de los estudios de perfiles e disolución comparativos

  • G Castañeda-Hernández, L Cruz-Antonio

United States Patent No . 6 , 306 , 900 B 1 . Enteric coated phar - aceutical compositions . October 23 , 2001

  • RR Alloway, R Isaacs, K Lake

Similar Papers

Loading similar papers…